303 related articles for article (PubMed ID: 12940534)
1. Clinical studies on the blockade of the renin-angiotensin-aldosterone-system.
Hennig L
Clin Nephrol; 2003 Jul; 60 Suppl 1():S53-8. PubMed ID: 12940534
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Weber MA
Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
[TBL] [Abstract][Full Text] [Related]
4. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
5. [Renin-angiotensin system modulation: instructions for use].
Bellis A; Rozza F; Crispo S; Trimarco B
G Ital Cardiol (Rome); 2008 Feb; 9(2):79-89. PubMed ID: 18383770
[TBL] [Abstract][Full Text] [Related]
6. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Bomback AS; Toto R
Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin receptor blockers: novel role in high-risk patients.
Javed U; Deedwania PC
Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
[TBL] [Abstract][Full Text] [Related]
9. [What is the purpose of dual or triple inhibition of the renin-angiotensin-aldosterone system?].
Legrand D; Krzesinski JM; Scheen AJ
Rev Med Suisse; 2008 Aug; 4(168):1792-7. PubMed ID: 18814762
[TBL] [Abstract][Full Text] [Related]
10. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update.
Arici M; Erdem Y
Am J Kidney Dis; 2009 Feb; 53(2):332-45. PubMed ID: 19166800
[TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
12. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
Karalliedde J; Viberti G
J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
[TBL] [Abstract][Full Text] [Related]
13. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
14. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
Nickenig G; Ostergren J; Struijker-Boudier H
J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S1-7. PubMed ID: 16969748
[TBL] [Abstract][Full Text] [Related]
15. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
16. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
17. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
Abuissa H; O'Keefe J
Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
[TBL] [Abstract][Full Text] [Related]
18. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
19. What is the role of angiotensin-receptor blockade in cardiovascular protection?
Cohn JN
Am Heart J; 2006 Nov; 152(5):859.e1-8. PubMed ID: 17070145
[TBL] [Abstract][Full Text] [Related]
20. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
Azizi M
Rev Prat; 2004 Jun; 54(11):1167-74. PubMed ID: 15496022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]